U.S. Personal Products Stock News

Credo Technology Group Holding’s PCIe 6.0-capable Toucan retimer has achieved PCI-SIG compliance, confirming it meets industry standards for the latest PCIe 6.0 technology. The company also introduced new connectivity products, including the Blue Heron 224G AI scale-up retimer and additional PCIe 6.0-capable devices aimed at AI and data center workloads. These launches focus on higher bandwidth and reliability for customers building AI clusters and advanced data center infrastructure. Credo...

If you are wondering whether Centuri Holdings' share price still reflects good value, or if the recent excitement has already been priced in, this article will walk you through what the numbers indicate about the stock. The shares last closed at US$31.24, with returns of 0.7% over 7 days, 10.0% over 30 days, 21.0% year to date and 72.1% over the past year. This has naturally raised questions about how the current price compares with underlying value. Recent news flow around Centuri Holdings...

What Proto Labs investors can glean from recent performance Proto Labs (PRLB) has moved sharply over the past year, with the stock returning 57.3% and showing double digit gains over the past month and past 3 months, catching the attention of many investors. Alongside that share price performance, the company reports annual revenue of US$533.1 million and net income of US$21.2 million, with recent annual revenue and net income growth rates of 6.4% and 24.4% respectively. See our latest...

If you are looking at Southern and wondering whether the current share price lines up with its underlying value, you are not alone. Southern's share price recently closed at US$95.18, with returns of 0.2% over 7 days, 8.7% over 30 days, 9.2% year to date, 10.6% over 1 year, 64.5% over 3 years and 98.5% over 5 years shaping how investors are thinking about its potential and risk. Recent coverage of Southern has focused on its position in the US utilities sector and the market's ongoing...

Vanda Pharmaceuticals recently received U.S. FDA approval for BYSANTI (milsaperidone) tablets, a new atypical antipsychotic for acute manic or mixed episodes in bipolar I disorder and for schizophrenia in adults, with U.S. commercial launch targeted for the third quarter of 2026 and marketing protection expected into 2044. BYSANTI’s status as a new chemical entity that rapidly converts to iloperidone, aligning with Fanapt’s established safety profile while offering dual active molecules,...

If you are wondering whether Trade Desk is starting to look attractively priced or still expensive, the recent share moves give you a lot to think about. The stock last closed at US$24.17, with returns of a 6.4% decline over 7 days, 33.9% decline over 30 days, 35.9% decline year to date and 67.4% decline over 1 year. The 3 year and 5 year returns sit at a 56.1% decline and 71.0% decline respectively. Recent news coverage has focused on Trade Desk's role in the broader digital advertising...

Regions Financial (RF) has drawn fresh attention after major firms including J.P. Morgan and UBS raised their views on the stock, even as recent quarterly results fell short of some market estimates. See our latest analysis for Regions Financial. At a share price of US$28.71, Regions Financial has recently seen a 12.94% 90 day share price return and a 27.80% 1 year total shareholder return, suggesting near term momentum alongside stronger multi year gains as investors reassess earnings...

Zymeworks recently reported positive Phase 3 results for zanidatamab in first-line HER2-positive gastroesophageal cancer, alongside year-end 2025 financials showing solid cash reserves and an existing US$125 million share repurchase authorization, while Redmile Group disclosed about US$70 million of share sales. Together, the encouraging late-stage clinical data, strengthened balance sheet, and ongoing buyback authorization highlight a shift toward reinforcing the company’s royalty-focused,...

What Zurn Elkay Water Solutions’ Recent Performance Signals for Investors Zurn Elkay Water Solutions (ZWS) has drawn fresh attention after a period of mixed short term returns, with the stock showing a 1 day decline, a small weekly pullback, yet gains over the past month and past 3 months. At a last close of US$49.93, the company sits on a 1 year total return of 44.56%. Longer horizons show very large gains over 3 and 5 years, alongside annual revenue of US$1.70b and net income of...

Clear Secure (NYSE:YOU) announced a collaboration with Mount Sinai Health System to roll out its CLEAR1 digital identity platform across the New York City based healthcare network. The agreement focuses on improving identity verification and check in for both patients and employees within one of the region's largest academic medical systems. Clear Secure, trading at $32.73, is best known for its airport security lanes, but this move signals a push into healthcare identity services. The...

Genuine Parts plans to separate into two independent, tax free companies by Q1 2027. The split will create a dedicated Global Automotive business and a separate Global Industrial business. The company expects the separation to sharpen business focus and reshape its long term direction. For NYSE:GPC shareholders, this planned breakup comes after a challenging stretch for the stock. Shares are at $116.16, with a 21.1% decline over the past week and a 15.6% decline over the past month. Over 3...

If you are wondering whether Collegium Pharmaceutical at around US$44.85 is good value or looking fully priced, the key is understanding how its current share price stacks up against a few different valuation checks. The stock has had a mixed run recently, with a 2.1% decline over the last 7 days and a 1.4% decline over the last 30 days, even though the 1 year return sits at 53.6% and the 3 year return at 67.4%. Recent attention on Collegium has focused on its position within the US...

In the past few days, law firm Kirby McInerney LLP announced it is investigating Alvotech and certain executives for potential federal securities law violations after the FDA issued a complete response letter citing a failed facility inspection for its AVT05 biologics license application. This combination of regulatory setback and investor scrutiny raises fresh questions about Alvotech’s quality controls, regulatory risk management, and disclosure practices around its biosimilar...

Griffon (GFF) is back in focus after fiscal Q1 results topped expectations, alongside a new AMES North America and Venanpri Tools joint venture, continued share buybacks, and the company’s 58th consecutive quarterly dividend. See our latest analysis for Griffon. Despite a 2.3% one day share price decline and a 7.5% 7 day share price pullback, Griffon’s 30 day and 90 day share price returns of 3.7% and 14.9% respectively, together with a 1 year total shareholder return of 22.4% and a 3 year...

MFA Financial (MFA) is on investor watch after posting annual revenue of US$325.4 million and net income of US$135.7 million, with recent returns mixed over the day, week, month and past 3 months. See our latest analysis for MFA Financial. At a share price of US$9.90, MFA Financial has seen short term share price softness alongside a positive 3 month share price return and a stronger 1 year total shareholder return of 11.27%. This suggests that recent price swings are occurring within a more...

Spectrum Brands Holdings (SPB) has drawn fresh attention after recent trading left the stock with a one-month return of 22% and a gain of 34.1% over the past three months, sharpening interest in its consumer brands portfolio. See our latest analysis for Spectrum Brands Holdings. That recent run sits on top of a 31.43% year to date share price return as the stock trades at US$78.91. The 1 year total shareholder return of 3.46% and 3 year total shareholder return of 33.70% suggest momentum has...

NasdaqGS:NDAQ has launched the Nasdaq Private Capital Indexes, a new suite of benchmarks for private markets. The indexes aim to provide greater transparency and standardized performance measurement for private capital investments. The launch is designed to serve institutional investors, consultants, and other market participants that use private market data. NasdaqGS:NDAQ operates as a global technology and market infrastructure provider, with data, analytics, and index services sitting...

The U.S. FDA is now reviewing Moderna’s mRNA flu vaccine application after previously issuing a Refusal to File tied to the study’s choice of comparator. This reversal reopens the regulatory path for Moderna’s mRNA flu program, which is part of the company’s broader respiratory vaccine portfolio. The shift follows public criticism of the initial decision and comes at a time when mRNA platforms remain central to Moderna’s long term product plans. For investors watching NasdaqGS:MRNA, this...

Advanced Energy Industries (NasdaqGS:AEIS) is actively pursuing acquisitions to expand its presence, with recent deals focused on industrial and medical technology. Management has highlighted a busy acquisition pipeline and points to recent integration of new technology as evidence that its inorganic growth push is gaining traction. The company is signaling that further deals in industrial and medical markets are a priority, with the goal of reshaping its portfolio around higher value...

If you are wondering whether Atmos Energy is attractively priced at its current level, this article will walk through what the market price might be saying about the stock. The shares last closed at US$181.72, with returns of 1.4% over 7 days, 9.9% over 30 days, 7.3% year to date, 24.4% over 1 year, 70.3% over 3 years and 140.1% over 5 years. Recent investor attention has focused on Atmos Energy as a regulated utility with a long standing role in US gas distribution. This has kept it in many...

Zacks recently upgraded McEwen to a Rank #2 (Buy), reflecting higher earnings estimates and signaling that analysts view its underlying operations more favorably than before. This shift in analyst sentiment places McEwen among the stronger names in the Zacks universe for earnings revisions, highlighting how changing expectations can influence market attention. We’ll now examine how this Zacks Rank upgrade, driven by improved earnings estimates, may influence McEwen’s existing investment...

If you are wondering whether OFG Bancorp at around US$41.39 is still good value or already pricing in a lot of optimism, you are asking the right question. The stock has had mixed recent returns, with a 1.2% decline over the last 7 days, an 11.4% gain over 30 days, 0.9% year to date, 2.4% over 1 year, 50.3% over 3 years and 134.3% over 5 years, which can change how investors think about both upside and risk. Recent news around OFG Bancorp has focused on its position as a US regional bank and...

If you are wondering whether Coty’s share price now reflects a fair deal or a value trap, you are not alone. This article focuses squarely on what the current valuation is really telling you. The stock recently closed at US$2.59, with returns of 3.2% over 7 days, a 22.9% decline over 30 days, a 16.7% decline year to date, and a 56.8% decline over 1 year, while the 3 year and 5 year returns stand at 76.9% and 67.9% declines respectively. Recent news around Coty has focused on its brand...

Ategrity Specialty Insurance Company Holdings (ASIC) has drawn fresh attention after a sharp recent move in its share price, with the stock up 6.1% over the past day and 32.7% in the past week. See our latest analysis for Ategrity Specialty Insurance Company Holdings. The recent surge in Ategrity Specialty Insurance Company Holdings’ share price, including a 32.7% 7 day share price return and a 23.97% 90 day share price return, suggests short term momentum is building while year to date...